Navigation Links
YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Date:12/10/2007

SAN DIEGO, Dec. 10 /PRNewswire/ -- YMed, Inc. announced today that it has successfully completed its first U.S. cases with its proprietary VascuTraK(TM) II PTA Dilatation Catheter. The VascuTraK(TM) II PTA Catheter is a unique 5F compatible, single operator rapid exchange system.

YMed's VascuTraK(TM) II catheter is designed and indicated for vascular intervention of a wide range of peripheral arteries including the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

"The VascuTraK(TM) II catheter is an important advancement in technology for the treatment of patients with peripheral vascular disease (PVD), especially below the knee where amputation risks are the greatest," says Dr. Rajesh Dave, Chairman, Endovascular Medicine, Harrisburg Hospital, Harrisburg, PA. Dr. Dave performed the initial clinical cases with commercially available VascuTraK(TM) II catheters. He noted that in some lesion subsets, including calcified lesions involving the popliteal artery, the VascuTraK(TM) II catheter was sufficient to complete the intervention without adjunctive devices that may increase restenois or require further intervention.

YMed plans to initiate U.S. Sales with a broad range of VascuTraK(TM) II PTA dilatation catheters during Q1 2008, says Richard Cooper, Vice President Sales & Marketing, YMed, Inc. "The VascuTraK(TM) II is the first PTA dilatation catheter to combine the features of plaque modification and longer balloon lengths," Mr. Cooper added. Balloon diameters range from 2.0 mm to 4.0 mm in 0.5 mm increments with balloon lengths of 20 mm to 120 mm.

YMed, Inc. is a privately held Corporation established in 2004. The company was founded and is managed by a highly experienced, multinational team of medical, engineering and business professionals from within the cardio and peripheral vascular industry. This team develops, manufactures and markets innovative products for vascular intervention provi
'/>"/>

SOURCE YMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...swire-FirstCall/ -- Roper Industries, Inc. (NYSE...nitive agreement to acquire Verathon, Inc., a lead...Verathon Board of Directors has approved the trans...ulatory approvals and closing conditions, includin...osing to be completed in early December. ,, He...
(Date:11/6/2009)...wswire-FirstCall/ -- Derma Sciences, Inc. (OTC...nd care products, announced plans to release its t... November 16, 2009. The Company will hold a confer...11:00 am EST. Interested parties should call (866)...nal), with passcode 81416481 to access the call. Y...
(Date:11/6/2009)...swire-FirstCall/ -- Virtual Health Technologies, I...t the previously confirmed Letter of Intent to sel...nt Technologies, Inc (WNDM) is subject to final ap... of VHGI. ,, Shareholder Assurances ,, "...lty stream and cash realized from the transaction ...
Breaking Medicine Technology:Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 1M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 2M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 3M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 4Mayo Clinic study shows people with heart devices can digest advanced diagnostic technology safely 60087 1Mayo Clinic study shows people with heart devices can digest advanced diagnostic technology safely 60087 2Mayo Clinic study shows people with heart devices can digest advanced diagnostic technology safely 60087 3Wolves lose their predatory edge in mid life new U of Minnesota study shows 60083 1Wolves lose their predatory edge in mid life new U of Minnesota study shows 60083 2
...mics, a leader in,developing automated molecular t...2C9-VKORC1 panel that it submitted to the FDA for ...uated by the Harvard Medical,School-Partners Healt...arfarin (also called Coumadin) is a drug prescribe...llion prescriptions per year, one of the,side effe...
... /PRNewswire-FirstCall/ --,Replidyne, Inc. announc...al trial using faropenem medoxomil (faropenem) in ...a common infection of the,middle ear. Initial anal...mary objective to show that faropenem was effectiv... to permit the dose,selection for Phase III trials...
Other Medicine Technology:Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity 2Replidyne Phase II Pediatric Trial Meets Primary Objective 2Replidyne Phase II Pediatric Trial Meets Primary Objective 3
(Date:11/9/2009)...wswire/ -- Davis Bregman , a pain management ph...dents of Manhattan in New York City. Patients wil...he office at 212-918-1629 or sending an email from...ble to see the doctor in the less stressful home s...f seeing most patients. The service will be fee f...
(Date:11/8/2009)...Newswire-USNewswire/ -- Today, the nation Mayors c...ing, the Affordable Health Care for America Act, a...tep in reforming America,s healthcare system. ,...eeting in Providence (RI), mayors from across the ...m principles of reducing the long-term growth of h...
(Date:11/8/2009)...ssage of Health Care Reform Bill ,, Critical ...erage for all Americans ,, HARRISBURG, Penn., ... Last night the United States House of Representa...on that would strengthen Medicare for seniors and ...ces millions of Americans out of affordable health...
(Date:11/8/2009)...ing Taxes Nail Nation,s Job Creators ,, WASHING... to U.S. House passage of the health care bill (H....uncil (SBE Council) president & CEO Karen Kerr...no mistake, those voting for H.R. 3962 voted to bu...nd crushing taxes and penalties. Even in the best ...
(Date:11/8/2009)... Global Solutions is pleased to announce that it h...l effort for ReSound who recently received an awar...act. The award includes not only the Veterans Admi... other federal agencies. , ...al Solutions is pleased to announce that it has be...
Breaking Medicine News(10 mins):Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:The Nation's Mayors Commend House Passage of Health Reform Bill 2Health News:AARP Pennsylvania Key Vote News Alert 2Health News:AARP Pennsylvania Key Vote News Alert 3Health News:AARP Pennsylvania Key Vote News Alert 4Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3
...inaga and Research Assistant Professor Hitoshi Ina... Okazaki, Japan) found that a sour taste receptor,... by acid stimulus but opened gate only after the r...journal, EMBO reports, on June 6, 2008. , They in...
... efforts to alleviate human suffering, the America...evelopment (LIFE), recently shipped an,entire fort...es to Somalia., In partnership with California-ba...ntal humanitarian,organizations, LIFE sent this sh...
...bilitation Services,the Most, ALEXANDRIA, Va., Ju...t exceptions process for clinically based care abo...f the U.S. House of,Representatives has endorsed l...hed 225 cosponsors. The bipartisan legislation was...
...Health Care Options,for Area Residents, BUTLER, P...aration funding and a better health insurance syst...Community and Economic,Development official helped...ght never have happened," DCED Deputy Secretary De...
...wberry-like patches that appear on the skin of inf...lop in 5%-10% of Caucasian infants and usually dis...schoff and colleagues, at Children,s Hospital Bost...rotein CD133 were isolated from infantile hemangio...
...ON, June 5 "After 32 years of delay,the Food and ...ith the law,and set a date to classify mercury ama...egnant women and unborn babies, and children. This...ow finish classification within one year of the cl...
Other Medicine News:Health News:Majority of U.S. House Supports Repeal of Medicare Therapy Caps 2Health News:DCED Official Helps to Break Ground for Hospital Expansion Project in Southwest PA 2Health News:US FDA Admits Risks of Mercury Dental Fillings, Settles Lawsuit 2
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
Medicine Products: